Zacks Investment Research on MSN23h
FDA Expands Exelixis Cabometyx Label for Neuroendocrine TumorsExelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback